Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer

Gynecologic Oncology

Volumn 65, Issue 1, 1997, Pages 130-137

  Codegoni, A M ^a   Broggini, M ^a   Pitelli, M R ^b   Pantarotto, M ^a   Torri, V ^a   Mangioni, C ^b   D'Incalci, M ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLADENINE; CYCLOPHOSPHAMIDE; DNA GLYCOSYLTRANSFERASE; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; GLUTATHIONE TRANSFERASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PLATINUM;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; DNA REPAIR; FEMALE; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN TISSUE; MORTALITY; NORTHERN BLOTTING; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA ANALYSIS;

EID: 0031128016     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1996.4609     Document Type: Article

References (48)

1. 1. Cannistra SA: Cancer of the ovary. N Engl J Med 329:1550-1559, 1993
2. 2. National Institutes of Health. Ovarian cancer: Screening, treatment and followup. NIH Consensus Statement 12(3):1-30, 1994
3. 3. Gottesman MM, Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385-427, 1993
4. 4. Meijer C, Mulder NH, de Vries EGE: The role of detoxifying systems in resistance of tumor cells to cisplatin and Adriamycin. Cancer Treat Rev 17:389-398, 1990
5. 5. Ten Bokkel Huinink WW: Current status of chemotherapy for ovarian carcinoma. Eur J Cancer Clin Oncol 24:583-585, 1988
6. 6. Bourhis J, Goldstein LJ, Riou G, Pastan I, Gottesmann MM, Bernard J: Expression of a human multidrug resistance gene in ovarian cancer carcinomas. Cancer Res 49:5062-5065, 1989
7. 7. Arao S, Suwa H, Mandai M, Tashiro H, Miyazaki K, Okamura H, Nomura H, Hiai H, Fukumoto M: Expression of multidrug resistance gene and localization of P-glycoprotein in human primary ovarian cancer. Cancer Res 54:1355-1359, 1994
8. 8. Godwin AK, Meister A, O'Dwyer PJ, Huang CS, Hamilton TC, Anderson ME: High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 89:3070-3074, 1992
9. 9. van der Zee AG, van Ommen B, Meijer C, Hollema H, van Bladeren PJ, de Vries EG: Glutathione S-transferase activity and isoenzyme composition in benign ovarian tumours, untreated malignant ovarian tumours, and malignant ovarian tumours after platinum/cyclophosphamide chemotherapy. Br J Cancer 66:930-936, 1992
10. 10. Green JA, Robertson LJ, Clark AH: Glutathione S-transferase expression in benign and malignant ovarian tumours. Br J Cancer 68:235-239, 1993
11. 11. van der Zee AG, Hollema H, Suurmeijer AJH, Krans M, Sluiter WJ, Willemse PHB, Aalders JG, Devries EGE: Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 13:70-78, 1995
12. 12. Murphy D, McGown AT, Hall A, Cattan A, Crowther D, Fox BW: Glutathione S-transferase activity and isoenzyme distribution in ovarian tumour biopsies taken before or after cytotoxic chemotherapy. Br J Cancer 66:937-942, 1992
13. 13. Schneider E, Hsiang YH Liu LF: DNA topoisomerases as anticancer drug targets. Adv Pharmacol 21:149-183, 1990
14. 14. Zunino F, Capranico G: DNA topoisomerase II as the primary target of antitumor anthracyclines. Anticancer Drug Des 5:307-317, 1990
15. 15. Fry AM, Chresta CM, Davies SM, Walker MC, Harris AL, Hartley JA, Master JRW, Hickson ID: Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res 51:6592-6595, 1991
16. 16. Potmesil M, Hsiang YH, Liu LF, Bank B, Grossberg H, Kirshenbaum S, Forlenzar TJ, Penziner A, Kanganis D, Knowles D, Traganos F, Silber R: Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II. Cancer Res 48:3537-3543, 1988
17. 17. van der Zee AG, de Vries EG, Hollema H, Kaye SB, Brown R, Keith WN: Molecular analysis of the topoisomerase II alpha gene and its expression in human ovarian cancer. Ann Oncol 5:75-81, 1994
18. 18. Lee SM, Harris M, Rennison J, McGown A, Bromley M, Elder RH, Rafferty JA, Crowther D, Margison GP: Expression of O6-alkylguanine-DNA-alkyltransferase in situ in ovarian and Hodgkin's tumours. Eur J Cancer 29A:1306-1312, 1993
19. 19. Chen SS, Citron M, Spiegel G, Yarosh D: O6-methylguanine-DNA methyltransferase in ovarian malignancy and its correlation with postoperative response to chemotherapy. Gynecol Oncol 52:172-174, 1994
20. 20. Matijasevic Z, Boosalis M, Mackay W, Samson L, Ludlum DB: Protection against chloroethylnitrosourea cytotoxicity by eukaryotic 3-methyl-adenine DNA glycosylase. Proc Natl Acad Sci USA 90:11855-11859, 1993
21. 21. Klungland A, Fairbairn L, Watson AJ, Margison GP, Seeberg E: Expression of the E. coli 3-methyladenine DNA glycosylase I gene in mammalian cells reduces the toxic and mutagenic effects of methylating agents. EMBO J 11:4439-4444, 1992
22. 22. Hoeijmakers JH: Nucleotide excision repair. II. From yeast to mammals. Trends Genet 9:211-217, 1993
23. 23. Dabholkar M, Vionnet J, Bostick Bruton F, Yu JJ, Reed E: Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 94:703-708, 1994
24. 24. Dabholkar M, Bostick Bruton F, Weber C, Bohr VA, Egwuagu C, Reed E: ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 84:1512-1517, 1992
25. 25. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ: Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 18:5294-5299, 1979
26. 26. Erba E, Ubezio P, Pepe S, Vaghi M, Marsoni S, Torri W, Mangioni C, Landoni F, D'Incalci M: Flow cytometric analysis of DNA content in human ovarian cancers. Br J Cancer 60:45-50, 1989
27. 27. Cox DR: Analysis of Binary Data. London, Methuen, 1970, pp 18-19
28. 28. Kaplan EL, Meier P: Non parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
29. 29. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-202, 1996
30. 30. A'Hern RP, Gore ME: Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol 13:726-732, 1995
31. 31. Ozols RF, Young RC: Chemotherapy of ovarian cancer. Semin Oncol 18:222-232, 1991
32. 32. Rowinsky EK, Donehower RC: Paclitaxel (Taxol). N Engl J Med 332:1004-1014, 1995
33. 33. Guastalla JP: Second-line chemotherapy in epithelial ovarian carcinoma: Platinum again? Taxanes? How to choose? Eur J Cancer 30A:1741-1744, 1994
34. 34. Scheffer GL, Wijngaard PLJ, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, Meijer C, Clevers HC, Scheper RJ: The drug resistance-related protein LRP is the human majour vault protein. Nat Med 1:578, 1995
35. 35. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV, Deeley RG: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650-1654, 1992
36. 36. Tagliabue G, Citti L, Massazza G, Damia G, Giavazzi R, D'Incalci M: Tumour levels of O6-alkylguanine-DNA-alkyltransferase and sensitivity to BCNU of human xenografts. Anticancer Res 12:2123-2125, 1992
37. 37. Citron M, Graver M, Schoenhaus M, Chen S, Decker R, Kleynerman L, Kahn LB, White A, Fornace AJJ, Yarosh D: Detection of messenger RNA from O6-methylguanine-DNA methyltransferase gene MGMT in human normal and tumor tissues. J Natl Cancer Inst 84:337-340, 1992
38. 38. Citron M, Decker R, Chen S, Schneider S, Graver M, Kleynerman L, Kahn LB, White A, Schoenhaus M, Yarosh D: O6-methylguanine-DNA methyltransferase in human normal and tumor tissue from brain, lung, and ovary. Cancer Res 51:4131-4134, 1991
39. 39. Pegg AE, Byers TL: Repair of DNA containing O6-alkylguanine. FASEB J 6:2302-2310, 1992
40. 40. Walker MC, Masters JR, Margison GP: O6-alkylguanine-DNA-alkyl-transferase activity and nitrosourea sensitivity in human cancer cell lines. Br J Cancer 66:840-843, 1992
41. 41. Habraken Y, Laval F: Increased resistance of the Chinese hamster mutant irs1 cells to monofunctional alkylating agents by transfection of the E. coli or mammalian N3-methyladenine-DNA-glycosylase genes. Mutat Res 293:187-195, 1993
42. 42. Ibeanu G, Hartenstein B, Dunn WC, Chang LY, Hofmann E, Coquerelle T, Mitra S, Kaina B: Overexpression of human DNA repair protein N-methylpurine-DNA glycosylase results in the increased removal of N-methylpurines in DNA without a concomitant increase in resistance to alkylating agents in Chinese hamster ovary cells. Carcinogenesis 13:1989-1995, 1992
43. 43. Imperatori L, Damia G, Taverna P, Garattini E, Citti L, Boldrini L, D'Incalci M: 3T3 NIH murine fibroblasts and B78 murine melanoma cells expressing the Escherichia coli N3-methyladenine-DNA glycosylase I do not become resistant to alkylating agents. Carcinogenesis 15:533-537, 1994
44. 44. Larminat F, Bohr VA: Role of the human ERCC-1 gene in gene-specific repair of cisplatin-induced DNA damage. Nucleic Acids Res 22:3005-3010, 1994
45. 45. Lee KB, Parker RJ, Bohr V, Cornelison T, Reed E: Cisplatin sensitivity/ resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3. Carcinogenesis 14:2177-2180, 1993
46. 46. Bramson J, Panasci LC: Effect of ERCC-1 overexpression on sensitivity of Chinese hamster ovary cells to DNA damaging agents. Cancer Res 53:3237-3240, 1993
47. 47. Dabholkar M, Vionnet J, Parker RJ, Bostick Bruton F, Dobbins A, Reed E: Expression of an alternatively spliced ERCC1 mRNA species is related to reduced DNA repair efficiency in human T lymphocytes. Oncol Rep 2:209-214, 1995
48. 48. Pantazis P, Kozielski AJ, Mendoza JT, Early JA, Hinz HR, Giovanella BC: Camptothecin derivatives induce regression of human ovarian carcinomas grown in nude mice and distinguish between non-tumorigenic and tumorigenic cells in vitro. Int J Cancer 53:863-871, 1993